KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $1.4 billion.

  • Moderna's Accumulated Expenses fell 14.39% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 14.39%. This contributed to the annual value of $1.4 billion for FY2024, which is 20.63% down from last year.
  • As of FY2024, Moderna's Accumulated Expenses stood at $1.4 billion, which was down 20.63% from $1.8 billion recorded in FY2023.
  • In the past 5 years, Moderna's Accumulated Expenses ranged from a high of $2.1 billion in FY2022 and a low of $470.0 million during FY2020.
  • In the last 3 years, Moderna's Accumulated Expenses had a median value of $1.8 billion in 2023 and averaged $1.8 billion.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 594.73% in 2020, then decreased by 20.63% in 2024.
  • Yearly analysis of 5 years shows Moderna's Accumulated Expenses stood at $470.0 million in 2020, then spiked by 213.19% to $1.5 billion in 2021, then skyrocketed by 42.73% to $2.1 billion in 2022, then declined by 14.42% to $1.8 billion in 2023, then fell by 20.63% to $1.4 billion in 2024.